Civetta Therapeutics, LLC

In December 2019, Civetta Therapeutics, LLC announced a $53 million Series A round financing. Civetta is a Cambridge, Massachusetts-based therapeutics company, founded to advance new medicines through small molecule targeting of beta-propeller domains with the goal of developing important drugs for cancers and other diseases.

Ribon Therapeutics

In February 2016, Deerfield invested in Ribon Therapeutics’ $24 million Series A preferred financing. Ribon is a discovery stage biotechnology company focused on a specific part of Poly Polymerases (PARPs) called monoPARP (mono ADP-ribose polymerase). These proteins are potential inhibitors to block cancer cells’ fundamental ability to survive under stress.

Appello Pharmaceuticals, Inc.

In June 2018, Deerfield invested in Appello Pharmaceuticals Inc., an early stage spin-out from Vanderbilt University that is advancing a new small molecule therapy for the symptomatic treatment of Parkinson’s disease. The investment supports the development of the positive allosteric modulators (“PAMs”) of the metabotropic glutamate receptor subtype 4 (“mGlu4”).

Vescor LLC

In January 2017, Deerfield and MD Anderson Cancer Center entered into a strategic collaboration to form Vescor Therapeutics. Vescor is focused on discovery and development of autophagy targeted therapeutics for cancer treatment. Autophagy is a cellular process that plays an important role during the development and maintenance of tumors. It allows tumors to scavenge nutrients to sustain growth and survival. Autophagy also has been demonstrated as critical to therapeutic resistance, and is upregulated during cancer treatment in response to chemotherapy and radiation.

Chondrial Therapeutics

In November 2016, Deerfield led a Series A financing in Chondrial Therapeutics. Chondrial is an emerging biotechnology company focused on the treatment of rare mitochondrial diseases, such as Friedreich’s Ataxia (FA). Concurrent with our financing, Chondrial announced the licensing of a novel investigational technology, CTI-1601, for the treatment of FA from Indiana University Research and Technology Corp. (IURTC) and Wake Forest University Health Sciences. FA is a progressive disease that affects multiple body systems, particularly the brain and heart. FA is the most common ataxia in man and is caused by a deficiency of a key protein, frataxin, which is normally present in the mitochondria of all tissues.

Humanity Health

Humanity Health works with patients, physicians, pharmaceutical companies and clinical research organizations to increase the efficiency, timeliness, consistency and quality of clinical trials. Humanity Health’s experienced staff of study coordinators manage all aspects of day-to-day clinical operations at physician sites while its dedicated patient recruitment function drives trial enrollment and works with patients to improve participant retention and compliance.

Recovery Centers of America

Recovery Centers of America was launched to transform the way treatment for substance abuse and behavioral disorders is delivered in the United States. The company’s management team brings an unparalleled blend of real estate, clinical, operational and marketing expertise that, coupled with Deerfield’s capital and the resources of the Deerfield Institute, will provide a truly unique platform for delivering on this vision.

Eclat Pharmaceuticals

Éclat Pharmaceuticals is a specialty pharmaceutical company focused on the development, approval and commercialization of niche brands and generic products. The company was founded in 2011 when Deerfield joined forces with Mike Anderson, a pharmaceutical company executive with over 40 years of experience, to develop several moderate risk / high reward products with unique accelerated paths to market.

Veterinary Practice Partners

Deerfield, in collaboration with its CEO, Rich Lester, founded VPP in 2011. Our shared vision was to create a differentiated veterinary practice management company based on a co-ownership model. This distinctive strategy served to generate a unique set of acquisition opportunities and promoted deep ongoing engagement from its veterinary partners that in turn allowed the company to consistently achieve above average same-store growth.